Pancreatic Beta-Cell Protection - Hot Targets & Pipeline Analysis

“Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of Pancreatic Beta-cell protection. The report covers hot targets & molecules in research for beta-cell protection in both Type-1 diabetes & Type-2 diabetes disease progression.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Diabetes Drug market. The report also provides strategic insights on medicines that are likely to have an impact on beta-cell protection treatment space and potentially alter standards of care in the foreseeable future.
Therapies that are presently available for diabetes focus on reducing the disease symptoms, but there is a huge unmet need for therapies that can either slow or prevent the beta cell loss as there is a rapid loss of cells in type 1 diabetes and progressive loss in type 2 diabetes patients
Currently, researchers are focusing on novel therapeutic strategies aimed at restoring, or at least preventing further loss of beta cell mass in beta cell deficit type 1 and type 2 diabetes patients as endogenous secretion of insulin is advantageous over exogenous insulin such as direct effect on hepatic (liver) glucose metabolism. Hence, it provides a tremendous opportunity for upcoming therapies specific to Beta-cell loss such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.